Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jul 1;10(13):2115-20.
doi: 10.4161/cc.10.13.16244. Epub 2011 Jul 1.

LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology

Alexa S Green  1 , Nicolas Chapuis, Catherine Lacombe, Patrick Mayeux, Didier Bouscary, Jerome Tamburini
Affiliations
Review

LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology

Alexa S Green et al. Cell Cycle. .

Abstract

The link between cancer and metabolism has been suggested for a long time but further evidence of this hypothesis came from the recent molecular characterization of the LKB1/AMPK signaling pathway as a tumor suppressor axis. Besides the discovery of somatic mutations in the LKB1 gene in certain type of cancers, a critical emerging point was that the LKB1/AMPK axis remains generally functional and could be stimulated by pharmacological molecules such as metformin in cancer cells. Notably, most of experimental evidence of the anti-tumor activity of AMPK agonists comes from the study of solid tumors such as breast or prostate cancers and only few data are available in hematological malignancies, although recent works emphasized the potential therapeutic value of AMPK agonists in this setting. Further basic research work should be conducted to elucidate the molecular targets of LKB1/AMPK responsible for its anti-tumor activity in parallel of conducting clinical trials using metformin, AICAR or new AMPK activating agents to explore the potential of the LKB1/AMPK signaling pathway as a new target for anticancer drug development.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms

LinkOut - more resources